A knock-in mouse model of gastrointestinal stromal tumor harboring Kit K641E

被引:120
作者
Rubin, BP
Antonescu, CR
Scott-Browne, JP
Comstock, ML
Gu, YS
Tanas, MR
Ware, CB
Woodell, J
机构
[1] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA
[2] Univ Washington, Med Ctr, Dept Radiat Oncol & Immunol, Seattle, WA 98195 USA
[3] Univ Washington, Med Ctr, Dept Comparat Med, Seattle, WA 98195 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
D O I
10.1158/0008-5472.CAN-05-0891
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A mouse model of gastrointestinal stromal tumor (GIST) has been developed by a knock-in gene targeting strategy, which introduced a Kit gene K641E mutation, originally identified in sporadic human GISTs and in the germ line of familial GIST syndrome patients. Homozygous and heterozygous Kit K641E mice develop gastrointestinal pathology with complete penetrance and all Kit K641E homozygotes die by age 30 weeks due to gastrointestinal obstruction by hyperplastic interstitial cells of Cajal (ICC) or GISTs. Heterozygous mice have less extensive ICC hyperplasia and smaller GISTs, suggesting a dose-response relationship between oncogenically activated Kit and ICC proliferation. Immunoprecipitation and Western blotting reveal GISTs to contain abundant phosphorylated/ activated Kit. In addition to ICC hyperplasia and GISTs, homozygous Kit K641E mice exhibit loss-of-function Kit phenotypes, including white coat color, decreased numbers of dermal mast cells, and sterility, indicating that despite its oncogenic activity the mutant form cannot accomplish many activities of the wild-type gene. Kit K641E reproduces the pathology associated with the familial GIST syndrome and thus is an excellent model to study Kit pathway activation, ICC biology, GIST pathogenesis, and preclinical validations of GIST therapies and mechanisms of drug resistance.
引用
收藏
页码:6631 / 6639
页数:9
相关论文
共 45 条
[1]  
Beghini A, 2001, CANCER, V92, P657, DOI 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO
[2]  
2-D
[3]   A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors [J].
Chen, LL ;
Trent, JC ;
Wu, EF ;
Fuller, GN ;
Ramdas, L ;
Zhang, W ;
Raymond, AK ;
Prieto, VG ;
Oyedeji, CO ;
Hunt, KK ;
Pollock, RE ;
Feig, BW ;
Hayes, KJ ;
Choi, H ;
Macapinlac, HA ;
Hittelman, W ;
Velasco, MA ;
Patel, S ;
Burgess, MA ;
Benjamin, RS ;
Frazier, ML .
CANCER RESEARCH, 2004, 64 (17) :5913-5919
[4]   KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size [J].
Corless, CL ;
McGreevey, L ;
Haley, A ;
Town, A ;
Heinrich, MC .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (05) :1567-1572
[5]   Imatinib as a paradigm of targeted therapies [J].
Druker, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :239S-245S
[6]   Diagnosis of gastrointestinal stromal tumors: A consensus approach [J].
Fletcher, CDM ;
Berman, JJ ;
Corless, C ;
Gorstein, F ;
Lasota, J ;
Longley, BJ ;
Miettinen, M ;
O'Leary, TJ ;
Remotti, H ;
Rubin, BP ;
Shmookler, B ;
Sobin, LH ;
Weiss, SW .
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2002, 10 (02) :81-89
[7]   Familial multiple gastrointestinal stromal tumours with associated abnormalities of the myenteric plexus layer and skeinoid fibres [J].
Handra-Luca, A ;
Fléjou, JF ;
Molas, G ;
Sauvanet, A ;
Belghiti, J ;
Degott, C ;
Terris, B .
HISTOPATHOLOGY, 2001, 39 (04) :359-363
[8]   Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies [J].
Heinrich, MC ;
Blanke, CD ;
Druker, BJ ;
Corless, CL .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1692-1703
[9]   PDGFRA activating mutations in gastrointestinal stromal tumors [J].
Heinrich, MC ;
Corless, CL ;
Duensing, A ;
McGreevey, L ;
Chen, CJ ;
Joseph, N ;
Singer, S ;
Griffith, DJ ;
Haley, A ;
Town, A ;
Demetri, GD ;
Fletcher, CDM ;
Fletcher, JA .
SCIENCE, 2003, 299 (5607) :708-710
[10]   Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J].
Heinrich, MC ;
Corless, CL ;
Demetri, GD ;
Blanke, CD ;
von Mehren, M ;
Joensuu, H ;
McGreevey, LS ;
Chen, CJ ;
Van den Abbeele, AD ;
Druker, BJ ;
Kiese, B ;
Eisenberg, B ;
Roberts, PJ ;
Singer, S ;
Fletcher, CDM ;
Silberman, S ;
Dimitrijevic, S ;
Fletcher, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4342-4349